Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Aletea Zago"'
Autor:
Marco Antônio Schilling, Adriana Wink, Ingrid Mito, Victor Hugo Lenz, Luciana Tagliari, Denise Pereira, Lisandra Dellacosta, Mariza Schaan, Adriana Zardo, Gilca Nachtigal, Waldir Veiga Pereira, Mario Sérgio Fernandes, Cheila Eickhof, Moema Nene, Tânia Hellwig, Virginia Maria Coser, Laura Fogliatto, Lucia Mariano da Rocha Silla, Dalnei Veiga Pereira, Aletea Zago, Marcelo Capra, Sabrina Wisenstein, Inez Guterrez, Roque Lorandi, Tito Vanelli
Publikováno v:
Blood. 112:4286-4286
CML is a well characterized disease with a known chromosomal abnormality. The inhibition of BCR-ABL protein tyrose kinase activity represented an advance in the treatment of this disease. Imatinib is effective in chronic, accelerated and blastic phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22a96fcf1af0992d997923d67cdcf708
https://doi.org/10.1182/blood.v112.11.4286.4286
https://doi.org/10.1182/blood.v112.11.4286.4286
Autor:
Marisa Schaan, Adriana Zardo, Denise Almeida, Laura Fogliatto, Ines Guterres, Adriana Winck, Marco Antônio Schilling, Mario Sérgio Fernandes, Aletea Zago, Sabrina Wisinteiner, Marcelo Capra, Tânia Hellwig, Lucia Mariano da Rocha Silla, Roque Lorandi
Publikováno v:
Blood. 108:4822-4822
Background: Imatinib mesylate (Glivec,Novartis), an inhibitor of Bcr-abl tyrosine kinase, is currently being used in the treatment of CML with hematological, cytogenetic and molecular response. In Brazil, this drug is approved by Health Department fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcd2f545a7e6918ece941826a9de4b14
https://doi.org/10.1182/blood.v108.11.4822.4822
https://doi.org/10.1182/blood.v108.11.4822.4822